

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Adverse Events Associated with Endoscopic Retrograde Cholangiopancreatography: Protocol for a Systematic Review and Meta-analysis

	1
Journal:	BMJ Open
Manuscript ID	bmjopen-2021-053302
Article Type:	Protocol
Date Submitted by the Author:	10-May-2021
Complete List of Authors:	Forbes, Nauzer; University of Calgary, Medicine Leontiadis, GI ; McMaster University, Vaska, Marcus; Alberta Health Services, Knowledge Resource Service; Elmunzer, B.; Medical University of South Carolina Yuan, Yuhong ; McMaster University, Bishay, Kirles; University of Calgary, Medicine Meng, Zhao Wu; University of Calgary, Medicine Iannuzzi, Jordan; University of Calgary, Medicine O'Sullivan, Dylan; University of Calgary, Medicine Mah, Brittany; University of Calgary, Medicine Partridge, Arun; University of Calgary, Medicine Keswani, Rajesh; Northwestern University Feinberg School of Medicine Wani, Sachin; University of Calgary, Medicine Heitman, Steven; University of Calgary, Medicine Hilsden, Robert; University of Calgary, Medicine
Keywords:	Endoscopy < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY, Pancreatic disease < GASTROENTEROLOGY

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

2		
3	1	
4 5	2	Adverse Events Associated with Endoscopic Retrograde
6	3	Cholangiopancreatography: Protocol for a Systematic Review and
7		
8	4	Meta-analysis
9	5	
10	6	Nauzer Forbes MD MSc ^{1,2} , Grigorios I. Leontiadis MD PhD ^{3,4} , Marcus Vaska MLIS ⁵ ,
11 12	7	B. Joseph Elmunzer MD MSc ⁶ , Yuhong Yuan PhD ⁴ , Kirles Bishay MD ^{1,2} , Zhao Wu Meng MD ^{1,2} ,
13	8	Jordan Iannuzzi MD ¹ , Dylan E. O'Sullivan PhD ^{2,7} , Brittany Mah BSc ¹ ,
14	9	Arun C.R. Partridge MD ¹ , Rajesh N. Keswani MD MS ⁸ , Sachin Wani MD ⁹ ,
15	10	Ronald J. Bridges MD ¹ , Steven J. Heitman MD MSc ^{1,2} , Robert J. Hilsden MD PhD ^{1,2} ,
16	11	Yibing Ruan PhD MPH ^{8,10} , Darren R. Brenner PhD ^{2,8,10}
17	12 13	
18	13	 Department of Medicine, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada
19	15	 Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, ON, Canada
20	16	4. Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada
21	17 18	 Knowledge Resource Service, Alberta Health Services, Calgary, AB, Canada Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC, USA
22	19	 Division of Gasci benefology and repatology, Medical University of South Caronna, Charleston, SC, OSA Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
23 24	20	8. Division of Gastroenterology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
24 25	21	9. Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
26	22 23	10. Department of Cancer Epidemiology and Prevention Research, Cancer Control Alberta, Alberta Health Services, Calgary, AB, Canada
27	20	
28	24	Corresponding Author:
29	24 25	
30	26 27	Nauzer Forbes, MD, MSc Assistant Professor of Medicine
31	27	Division of Gastroenterology
32	29	University of Calgary
33	30	TRW 6D19, 3280 Hospital Drive NW
34	31	Calgary, AB T2N 4Z6
35	32	Tel: 403.592.5089 Fax: 403.592.5090
36 37	33	E-mail: nauzer.forbes@ucalgary.ca
38	34	
39	35	AUTHOR CONTRIBUTIONS
40	36	conception and design: NF, GIL
41	37	• analysis plan: NF, GIL, MV, YY, DEO, BJE, DRB
42	38	drafting of the article: NF
43	39	critical revision of the article for important intellectual content: all authors
44	40	final approval of the article: all authors
45	41	
46 47	42	DISCLOSURES/ CONFLICTS OF INTEREST
47 48	43	None relevant.
49	44	
50	45	FUNDING
51	46	The N.B. Hershfield Chair in Therapeutic Endoscopy (Grant number not applicable – N/A).
52	47	
53	48	WORD COUNT
54	49	243 (abstract); 2,590 (main text).
55 56	50	
56 57	50	
57		
59		
60		For peer review only - http://bmiopen.bmi.com/site/about/quidelines.xhtml

60

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is performed to diagnose and manage conditions of the biliary and pancreatic ducts. Though effective, it is associated with common adverse events (AEs). The purpose of this study is to systematically review ERCP AE rates and report up-to-date pooled estimates.

Methods and Analysis

A comprehensive electronic search will be conducted. A study team of eight data abstracters will independently determine study eligibility, assess quality, and abstract data in parallel, with any two concordant entries constituting agreement and with discrepancies resolved by consensus. The primary outcome will be the pooled incidence of post-ERCP pancreatitis (PEP), with secondary outcomes including post-ERCP bleeding, cholangitis, perforation, cholecystitis, sedation-related cardio-pulmonary events, and unplanned healthcare encounters (UHE). Secondary outcomes will also include rates of specific and overall adverse events within clinically relevant subgroups determined *a priori*. DerSimonian and Laird random effects models will be used to perform meta-analyses of these outcomes. Sources of heterogeneity will be explored via meta-regression. Subgroup analyses based on median dates of data collection across studies will be performed to determine whether AE rates have changed over time.

23 Conclusion

Given that ERCP is widely performed around the world, endoscopists and patients should have access to up-to-date estimates of procedural risk. Our meta-analysis will bridge these important knowledge gaps so that all relevant stakeholders are well-informed.

28 PROSPERO Registration Number

CRD42020220221.

1		
2 3	1	Keywords
4 5	2	ERCP; endoscopic retrograde cholangiopancreatography; adverse event;
6 7	3	pancreatitis; hemorrhage; cholangitis.
8 9	4	
10 11	5	
12 13		
14 15	6	
16	7	
17 18	8	
19 20	9	
21 22		
23 24	10	
25 26	11	
27 28	12	
29 30	13	
31		
32 33	14	
34 35	15	
36 37	16	
38 39	17	
40 41		
42 43	18	
44 45	19	
46 47	20	
48	21	
49 50	22	
51 52		
53 54	23	
55 56	24	
57 58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
3	1	ARTICLE SUMMARY
4 5	2	
6 7	3	Strengths and Limitations of the Proposed Study
8 9	4	• Our meta-analysis will provide to up-to-date estimates of procedural risks
10 11	5	associated with the performance of ERCP.
12	6	• A comprehensive search strategy will be employed to capture all relevant studies
13 14	7	and answer our study question.
15 16	8	• The strength of the body of evidence will be assessed using the Grading of
17 18	9	Recommendations, Assessment, Development and Evaluation (GRADE) framework.
19 20	10	• A limitation of our approach is the likelihood of pooling outcome estimates using
21	11	variable definitions of outcomes across studies, which we will partially mitigate by
22 23	12	performing sensitivity analyses based on outcome definitions.
24 25	13	• We have also made the decision to exclude conference abstracts from our study.
26 27	14	Though this potentially disposes to publication bias, we feel that the unclear or
28 29	15	ambiguous methodology often available from conference abstracts would add to
30	16	potential study heterogeneity.
31 32	17	
33 34	18	
35 36	19	
37 38	20	
39	21	
40 41	22	
42 43	23	
44 45	24	
46 47	25	
48	26	
49 50	27	
51 52	28	
53 54	29	
55 56	30	
57		
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

INTRODUCTION

Endoscopic retrograde cholangiopancreatography (ERCP) is an essential and commonly performed advanced endoscopic procedure used in the diagnosis and treatment of several categories of biliary and pancreatic pathology.^[1-4] Although the role of standard ERCP has transitioned to that of a primarily therapeutic procedure, ERCP volumes have nevertheless risen over the past 10-15 years in the United States (US).^[5,6] ERCP is performed across high- and low-volume centers, and by endoscopists of variable experience and specialties.^[7] A steep learning curve during a specialized period of training results in an advanced skill set required to perform safe and effective ERCP.^[8, 9]

While very effective overall,^[10] ERCP is widely known to have the highest adverse event (AE) profile among all commonly performed endoscopic procedures, with a collective AE rate of >10%.^[11] Common AEs include post-ERCP pancreatitis (PEP), bleeding, infection, cholecystitis, perforation, and cardiopulmonary events.^[11, 12] PEP is the most common, with estimated rates of 5-10% in all-comers, approaching or exceeding 20% in higher-risk cases.^[11-13] Despite an emphasis on training and quality, both the incidence of PEP and its associated mortality are rising in the US.^[14] Rates of post-ERCP bleeding range between 0.3% and 2%.^[15-17] Symptomatic post-ERCP infection (cholangitis with or without sepsis) is also a common AE following ERCP, with a reported range between 0.5% and 3%^[11] and is of particular interest in recent years given the rise of duodenoscope-related infections.^[18-21]

ERCP AEs are commonly reported in studies of varying designs; however, few systematic reviews have synthesized available incidence rates of specific or overall AEs following ERCPs. A 2015 study synthesized the rates of PEP from randomized trials,^[13] but their search is now nearly 8 years out of date. Furthermore, other adverse event rates were not considered, and observational studies were not included. Observational studies are a required element of understanding true population rates of AEs.^[22, 23] given that the patient mixes therein are more representative of the actual patient population in clinical practice compared to the highly selected participants in randomized trials. Given the frequency with which these events occur and their significant burden on the healthcare system,^[24, 25] it is crucial to obtain accurate, up-to-date data on which to base estimates of incidence. Furthermore, AE rates differ depending on clinically relevant patient- and procedure-related parameters, but pooled estimates of incidences within these subgroups are unavailable.

Page 7 of 24

BMJ Open

These estimates could be important so that patients and endoscopists are aware of specific risks associated with each procedure. Therefore, we propose a systematic review and meta-analysis to determine the incidence of adverse events following ERCP, both overall and within clinically relevant patient- and procedure-related subgroups. **METHODS Overview and Objectives** Our meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) recommendations.^[26, 27] Our protocol has been registered on PROSPERO (CRD42020220221). The primary objective will be to determine the pooled overall incidence of PEP in adult patients undergoing ERCP. The secondary objectives will be to determine the pooled incidences of post-ERCP bleeding, cholangitis, perforation, cholecystitis, sedation-related cardio-pulmonary events, unplanned healthcare encounters, and death, in addition to determining the rates of specific and overall adverse events within clinically relevant subgroups determined *a priori* and described below. No research ethics approval is required for this study given the lack of patient-specific data being collected. **Eligibility Criteria**

Given the comprehensive nature of the study question and outcomes of interest, two separate electronic searches will be conducted, with studies captured within either search being eligible for inclusion in the overall systematic review. The first search will focus on randomized trials only, while the second search will also include observational studies. For the first search, a study will be included in the final review if it meets ALL of the following criteria: (1) it presents original data in the form of a randomized clinical trial (with any primary research question), (2) the interventional arm or control arm represents adult patients receiving ERCP, (3) it makes reference to the determination of overall or specific ERCP-related adverse event(s) as a primary or secondary outcome; (4) it reports the incidence of at least one post-ERCP adverse event (including any of PEP, bleeding, symptomatic infection or cholangitis, perforation, cholecystitis, sedation-related cardio-

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

pulmonary events, death, or unplanned presentation to a healthcare facility within any follow-up period up to 30 days after the index procedure); (5) it is published in English; and (6) at least 75% of study patients received their ERCP in the year 2000 or later. The year 2000 was chosen as a cut-off so that only studies representative of the current 'era' of ERCP are included. For the first search, a study will be excluded from the review if (1) it is a conference abstract; or (2) if it reports data that overlaps with another study's patient population in part or in whole for the same outcome of interest. In the latter case, the study that includes the largest number of patients that had their ERCP conducted in the year 2000 or later will be included while any others are excluded.

For the second search, a study will be included in the final review if it meets ALL of the following criteria: (1) it is an observational study of any design; (2) its primary or secondary objective is to assess post-ERCP adverse event rates or outcomes in adults; (3) it reports the incidence of a specific post-ERCP adverse event, including any of the following: PEP, bleeding, symptomatic infection or cholangitis, perforation, cholecystitis, sedation-related cardio-pulmonary events, and unplanned presentation to a healthcare facility within 30 days of the index procedure; (4) it is published in English; and (5) at least 75% of study patients received their ERCP in the year 2000 or later. For the second search, a study will be excluded from the review if it meets ANY of the following criteria: (1) it is a case report; (2) it is a smaller study (fewer than 500 total study patients, with this threshold set to mitigate small study effects due to random error and to reduce the likelihood of including zero-event studies, which are problematic to meta-analyze); (3) it represents the experience of a single endoscopist; (4) it is a conference abstract; or (5) it reports data that overlaps with another study's patient population in part or in whole for the same outcome. In the latter case, the study that includes the largest number of patients that had their ERCP conducted in the year 2000 or later will be included while any others are excluded. Eligibility criteria for both aspects of the overall search strategy are summarized in **Table 1**.

28 Search Strategy and Terms

A comprehensive electronic search will be designed by a health research librarian and
carried out in the electronic databases MEDLINE (Ovid), PubMed, CINAHL, EMBASE, Scopus,
Web of Science, and Evidence Based Medicine (EBM) Reviews based on the eligibility criteria

Page 9 of 24

BMJ Open

detailed above, from inception of each data source to the search date. English language
citations from 2000 or later will be included. A combination of Medical Subject Heading
(MeSH) and free-text terms will be used along with spelling variations and synonyms to
create the two search strategies outlined above. A detailed list of search terms is provided in
Table 2, with a full search planning document provided in the Supplementary Materials.

Study Selection and Data Abstraction

All citations will be imported into DistillerSR (Evidence Partners, Ottawa, Canada) and any duplicate entries will be removed. Given the large volume of anticipated citations identified in the initial searches, 7 reviewers (KB, ZWM, JCD, JI, DEO, BM, AP) will be randomly assigned roughly equal numbers of citations and will independently screen titles and abstracts to identify citations for full-text review. A vote of 'both include' or 'both exclude' by any 2 of the 8 reviewers will be considered definitive. Discrepancies will be resolved by consensus of an *a priori* committee of study investigators (NF, YR, DRB). All included citations will then undergo independent duplicate full-text inclusion or exclusion by 2 reviewers (of the same pool of 8), with discrepancies again being resolved by consensus. Data will then be extracted into standardized abstraction forms in duplicate, with separate forms for each aspect of the search strategy. Forms will include authors, year of publication, study design, country(ies) in which the research was carried out, study setting, recruitment period, sample sizes, patient sex, age, and comorbidity, procedural indication(s), description of intervention(s), rates of adverse events (in absolute numbers and proportions), outcome definitions and follow-up periods. Data will be abstracted both on the patient level as well as the procedure level, as available. Relevant subgroups (Table 3) will also be abstracted.

25 Outcome Definitions

A particular challenge with pooling rates of ERCP AEs is that non-universal definitions of outcomes are employed across studies. Detailed study-specific outcome definitions will be abstracted to help address this issue. Outcome definitions will be compared against those described in the American Society for Gastrointestinal Endoscopy (ASGE) Lexicon.^[28] Studies not reporting clear outcomes definitions or those employing non-lexicon definitions will be

flagged for sensitivity analyses. Study-specific mechanisms of outcome capture will also be
 abstracted so that these can be considered separately.^[29]

4 Risk of Bias

Two authors will independently conduct risk of bias assessments for all included studies. Assessment of included randomized studies will be performed using the Cochrane Risk of Bias tool, version 2 (RoB 2),^[29] while the quality of observational studies will be assessed using the ROBINS-I tool.^[30] Discrepancies will be resolved by consensus.

10 Statistical Analysis, Subgroup and Sensitivity Analyses

We will perform DerSimonian and Laird random effects meta-analyses to report the pooled incidence rates of individual post-ERCP AEs along with 95% confidence intervals (CIs). Incidence rates from observational studies and randomized trials will be pooled separately (at no point being combined). Subgroup analyses will be performed using relevant study-, procedure- and patient-related characteristics selected *a priori*. These are summarized in Table 3. Sources of heterogeneity will also be tested by performing meta-regression. To determine whether adverse event rates have changed over time, we will perform subgroup analyses based on the median dates of data collection in individual studies for each type of adverse event. Median data collection will be assigned a single value per study and studies will be separated into three periods: a) 2000-2009, b) 2010-2014, and c) 2015-present. Meta-regression will be performed to determine whether there are any significant differences in specific or overall AE rates between periods. Periods were chosen based on the 2012 publication of the seminal manuscript on rectal non-steroidal antiinflammatory agents to prevent PEP^[31] and a 3-year lag period between study dissemination and clinical practice adoption.

We will also conduct a series of sensitivity analyses whereby studies of varying quality as per ROBINS-I and RoB 2 are considered separately and whereby studies employing non-ASGE-lexicon AE definitions will be considered separately. Inter-study heterogeneity will be assessed using the Cochrane *I*² statistic. Publication bias will be assessed by visual inspection of funnel plots in addition to performing Egger's and Begg's tests.^[32, 33] The statistical packages Revman 5.1 (Cochrane Collaboration) and Stata 14.0 Page 11 of 24

BMJ Open

(StataCorp) will be used for all analyses. The strength of the body of evidence will then be
 assessed using the Grading of Recommendations, Assessment, Development and Evaluation
 (GRADE) framework.^[34]

Patient and Public Involvement

No patients or public involved.

DISCUSSION


This systematic review and meta-analysis will provide up-to-date estimates of incidences of the most common adverse events associated with the performance of ERCP. Though ERCP in 2020 is primarily a therapeutic procedure, with minimal diagnostic indications, it remains one of the most commonly performed endoscopic procedures in the US and world-wide, with volumes having increased over time.^[5, 6] Even though ERCP is a relatively safe procedure overall, AEs are more prevalent with its performance than any other endoscopic procedure. Thus, it behowes endoscopists performing ERCP to be acutely aware of the most precise and up-to-date estimates of risk possible. If possible, patient- and procedure-specific estimates of risk should also be ascertained, which is also a goal of the proposed study. Obtaining these estimates could help set up appropriate patient expectations of risk and could also serve to optimize the peri-procedural management of ERCP patients.

Specific knowledge gaps are particularly important to bridge regarding ERCP AEs. In particular, accurate estimates of the rate of post-ERCP symptomatic infections (cholangitis or sepsis) are particularly important given the growing concerns around duodenoscope-related infections.^[18-21] Obtaining accurate estimates of the overall burden of post-ERCP infection is the first step toward describing the relatively smaller infection risk attributable directly to duodenoscope contamination and transmission. Similarly, estimates of post-sphincterotomy and/or post-sphincteroplasty bleeding are variable,^[15-17] and no pooled estimates to date are available. With regards to rarer AEs such as cholecystitis and perforation, evidence is even more scarce. Thus, an urgent but unmet need is present to accurately define the overall and specific AE profile associated with ERCP.

Though this protocol was designed to limit sources of bias through rigorous methodology, there are nevertheless potential limitations that require acknowledgment. As with any meta-analysis, the certainty of pooled estimates is limited by the quality of input studies. With this topic in particular, it is anticipated that study cohorts will be described using variable levels of detail regarding demographics, comorbidities, procedural indications, and procedural interventions. To mitigate this, we divided our study into two main analyses; the first, inclusive of randomized controlled trials, is expected to be more granular in terms of these details and is thus expected to yield more robust patient- and procedure-specific estimates of risk. The second, inclusive of only large observational studies, is expected to yield more pragmatic 'real-world' estimates of risk. For this analysis, a pre-set cutoff point of 500 patients was chosen to mitigate small study effects.

Another limitation of our approach is the possibility of pooling outcome estimates using variable definitions of outcomes across studies. To mitigate this, we will abstract study-specific outcome definitions and perform sensitivity analyses whereby studies with unclear or absent definitions are separately analyzed. Even with this approach, we expect there to be some degree of (acceptable) variability between study definitions, but we will compare study-specific definitions against the ASGE Lexicon's AE definitions^[28] to ensure that we only pool studies adhering to minimal thresholds for attribution of AEs. For instance, for post-ERCP bleeding, we will ensure that at minimum, studies require a hemoglobin drop of > 2 g as part of their definition, in order to prevent inclusion of patients with intraprocedural or non-clinically-significant post-procedural bleeding, which has been demonstrated to be of limited consequence.^[12] Another limitation includes missing studies due to our decision to restrict our inclusions to English studies with the majority of data collected after the year 2000. While this is a valid concern, we felt it was more important to capture evidence most representative of current practices, techniques and technologies. Therefore, studies with a significant volume of study procedures performed prior to the year 2000 were deemed to be at risk of not representing current ERCP practice. Finally, we have made the decision to exclude conference abstracts from our study. Though this potentially disposes to publication bias, we feel that the unclear or ambiguous methodology often available from conference abstracts would add to potential study heterogeneity.

Overall, despite these limitations, we anticipate that our study will bridge important knowledge gaps pertaining to ERCP-associated adverse events. Our results could potentially improve patient care and satisfaction by providing more detailed and up-to-date estimates LUR. s includin, g and practice s. of ERCP-related risk. Accurate AE estimates will also facilitate the design of future prospective ERCP studies including randomized trials and could potentially have meaningful implications on training and practice standards.



Г		
	Inclusion criteria	Exclusion criteria
Search Aspect 1	 original data randomized controlled trial (with any research question) interventional OR control arm of RCT represents adult patients receiving ERCP an adverse event is a primary and/or secondary outcome 	 non-English publication data overlaps with data from another study (in part or in whole) over 25% of study procedures performed prior to 2000 conference abstract
Search Aspect 2	 original data observational study (prospective or retrospective) reports on adult patients receiving ERCP primary or secondary objective of study is determination of ERCP adverse event(s) 	 small cohort of patients (fewer than 500) represents the experience of a single endoscopist non-English publication data overlaps with data from another study (in part or in whole) over 25% of study procedures performed prior to 2000 conference abstract
1 RCT, randomized	controlled trial; ERCP, endoscopic retrograde c	
2 3 4 5 6 7 8 9		
.0		
1		
2		
3		
4		
5		
6		
	For peer review only - http://bmjopen.bmj.com/	/site/about/guidelines.xhtml

Search Aspect 1: Randomized Controlled Trials
(ERCP OR "endoscopic retrograde cholangiopancreatography") \rightarrow limit to RCTs
(ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" OR "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post- endoscopic retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OR haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystiti OR perforation OR cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation OR cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complication*" OR "treatment outcome*" OR inflammation OR rupture)→limit to RCTs
Search Aspect 2: Observational Studies
(ERCP OR "endoscopic retrograde cholangiopancreatography")→limit to cohort/observational studies
(ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" OR "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post- endoscopic retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OR haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystiti OR perforation OR cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation OR cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complication*" OR "treatment outcome*" OR inflammation OR rupture)→limit to cohort/observational studies
*Full electronic search strategy provided in Supplementary Materials .

2
2
4
5
6
7
8
9
10
11
12
13
14 15
15 16
17
18
19
20
21
22
22 23
24
25
26
27
28
29 30
30 31
32
33
34
35
36
36 37
38
39
40
41
42
43
44 45
45 46
40 47
48
49
50
51
52
53
54
55
56
57
58
59 60
60

2_

Tab	ele 3. Planned subgroup analyses.
Category	Subgroups
Patient demographics and characteristics	 Female versus male sex Age < 50 versus ≥ 50 Inpatient versus outpatient status Degree of comorbidity (Charlson Comorbidity Index or other, TBD) Underlying primary sclerosing cholangitis Liver transplant status Presence of antiplatelet or anticoagulant medications Presence versus absence of PEP prophylaxis
Practice settings	 Academic institutions versus community practices Low-volume versus high-volume centers and/or endoscopists (cutoff points TBD)
Procedural indications	 Pancreatic versus biliary indications Choledocholithiasis (suspected or confirmed) Malignant obstruction Benign obstruction
Intra-procedural techniques	 Sphincterotomy Sphincteroplasty Pre-cut sphincterotomy Needle knife papillotomy Biliary stent placement Mechanical lithotripsy Cholangioscopy and/or pancreatoscopy Pancreatic versus common bile duct cannulation
Study methodology	 North American versus European versus Asian-Pacific Study publication date Median data collection date (2000-2009, 2010-2014, 2015-present) Study design (retrospective versus prospective observational versus randomized controlled trial) ASGE Lexicon versus non-lexicon definition(s) of outcomes
PEP, post-ERCP pancreatitis; TBD, to	o be determined; ASGE, American Society for Gastrointestinal Endoscopy.

1 2			
2 3 4	1	REFE	RENCES
5 6	2	[1]	Maple JT, Ikenberry SO, Anderson MA, et al. The role of endoscopy in the management
7	3	501	of choledocholithiasis. Gastrointest Endosc 2011;74:731-44.
8	4	[2]	Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of
9 10	5		the biliary tract and the pancreas. Gastrointest Endosc 2005;62:1-8.
11	6	[3]	Anderson MA, Appalaneni V, Ben-Menachem T, et al. The role of endoscopy in the
12	7		evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc
13	8		2013;77:167-74.
14	9	[4]	Chandrasekhara V, Chathadi KV, Acosta RD, et al. The role of endoscopy in benign
15 16	10		pancreatic disease. Gastrointest Endosc 2015;82:203-14.
16 17	11	[5]	Kröner PT, Bilal M, Samuel R, et al. Use of ERCP in the United States over the past
18	12	5 4 3	decade. Endosc Int Open 2020;8:E761-e769.
19	13	[6]	Ahmed M, Kanotra R, Savani GT, et al. Utilization trends in inpatient endoscopic
20	14		retrograde cholangiopancreatography (ERCP): A cross-sectional US experience.
21	15		Endosc Int Open 2017;5:E261-e271.
22 23	16	[7]	Testoni PA, Mariani A, Giussani A, et al. Risk factors for post-ERCP pancreatitis in
23 24	17		high- and low-volume centers and among expert and non-expert operators: a
25	18	[0]	prospective multicenter study. Am J Gastroenterol 2010;105:1753-61.
26	19	[8]	Wani S, Keswani RN, Han S, et al. Competence in Endoscopic Ultrasound and
27	20		Endoscopic Retrograde Cholangiopancreatography, From Training Through
28	21	[0]	Independent Practice. Gastroenterology 2018;155:1483-1494.e7.
29 30	22	[9]	Wani S, Han S, Simon V, et al. Setting minimum standards for training in EUS and
31	23		ERCP: results from a prospective multicenter study evaluating learning curves and
32	24 25		competence among advanced endoscopy trainees. Gastrointest Endosc
33	25	[10]	2019;89:1160-1168.e9.
34 35	26 27	[10]	Mariani A, Segato S, Anderloni A, et al. Prospective evaluation of ERCP performance
35 36	27 28	[11]	in an Italian regional database study. Dig Liver Dis 2019;51:978-984.
37	28 29	[11]	Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Adverse events associated with ERCP. Gastrointest Endosc 2017;85:32-47.
38	30	[12]	Rustagi T, Jamidar PA. Endoscopic retrograde cholangiopancreatography-related
39	31	[12]	adverse events: general overview. Gastrointest Endosc Clin N Am 2015;25:97-106.
40 41	32	[13]	Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, and mortality of post-
41	33	[15]	ERCP pancreatitis: a systematic review by using randomized, controlled trials.
43	34		Gastrointest Endosc 2015;81:143-149.e9.
44	35	[14]	Mutneja H, Vohra I, Go A, et al. Temporal Trends and Mortality of Post-Endoscopic
45	36	[11]	Retrograde Cholangiopancreatography Pancreatitis in the United States: A
46	37		Nationwide Analysis. Endoscopy 2020.
47 48	38	[15]	Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a
49	39		multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc
50	40		2009;70:80-8.
51	41	[16]	Christensen M, Matzen P, Schulze S, et al. Complications of ERCP: a prospective study.
52	42	[=0]	Gastrointest Endosc 2004;60:721-31.
53 54	43	[17]	Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary
55	44	[-,]	sphincterotomy. N Engl J Med 1996;335:909-18.
56	-		· · · · · · · · · · · · · · · · · · ·
57			
58			
59			1

 [18] Preventable tragedies: Superbugs and How Ineffective Monitoring of Medical Device Safety Fails Patients In: U.S. Senate Health E, Labor, and Pensions Committee, ed, 2016.
 [19] Muscarella LF. Risk of transmission of carbapenem-resistant Enterobacteriaceae and related "superbugs" during gastrointestinal endoscopy. World J Gastrointest Endosc 2014:6:457-74.

1 2 3

4

5

6

7 8

9

10

11

12

13

14

47

48 49

50

51 52

53 54

60

41

42

- 7 [20] Humphries RM, McDonnell G. Superbugs on Duodenoscopes: the Challenge of
 8 Cleaning and Disinfection of Reusable Devices. J Clin Microbiol 2015;53:3118-25.
- 9 [21] Forbes N, Heitman S, McCulloch P. Infection Control in ERCP: a Human Factors
 10 Perspective. Clin Transl Gastroenterol 2020;11:e00214.
- 11 [22] Page MJ, McKenzie JE, Kirkham J, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev 2014:Mr000035.
- 18 19 Interventions, openative batabase syst nev bornaneocoss.
 19 14 [23] Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011;8:e1001026.
- I7 [24] Fagenholz PJ, Fernández-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas 2007;35:302-7.
- Inamdar S, Sejpal DV, Ullah M, et al. Weekend vs. Weekday Admissions for Cholangitis
 Requiring an ERCP: Comparison of Outcomes in a National Cohort. Am J Gastroenterol
 2016;111:405-10.
- 2822[26]Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review2923and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
- 24 [27] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000;283:2008-12.
- 27 [28] Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events:
 28 report of an ASGE workshop. Gastrointest Endosc 2010;71:446-54.
- ³⁶ 29 [29] Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, 2011.
- 37 30 [30]
 38 31 39 31
 39 31 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30 51
 30
- 32[31]Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal4133indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-22.
- 42 34 [32] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
 43 35 graphical test. Bmj 1997;315:629-34.
 44 26 [22] Bogg CP. Magumdar M. Operating characteristics of a rank correlation test for
- 36 [33] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
 37 [34] Device CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
 - 38 [34] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating
 39 quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
 40

Keywords	
Concept	Synonym
ERCP	ERCP [Keyword]; "endoscopic retrog cholangiopancreatography" [Keywo cholangiopancreatography, endosco retrograde [MeSH]
Adverse Events	 "adverse event*" [Keyword]; "adverse effect*" [Keyword]; "adverse reaction [Keyword]; long term adverse effects. [MeSH]; "post-ERCP pancreatitis" [Keyword]; "post-endoscopic retroge cholangiopancreatography pancreat [Keyword]; pancreatitis [Keyword, MeSH]; haemorrhage [Keyword, MeSH]; haemorrhage [Keyword]; cholangitis [Keyword, MeSH]; bleeding [Keyword infection* [Keyword]; infections [Mecholecystitis [Keyword, MeSH]; perfections [Keyword]; cardiopulmonary [Keyw sepsis [Keyword, MeSH]; complication [Keyword]; unplanned [Keyword]; e [Keyword]; sedation [Keyword]; e [Keyword]; sedation [Keyword]; cholecystectomy [Keyword, MeSH]; choledocholithiasis [Keyword, MeSH]; choledocholithiasis [Keyword, MeSH]; mostoperative complication*" [Keyword]; treatment outcome [MeSH]; inflamm [Keyword, MeSH]; rupture [Keyword]; treatment outcome [MeSH]; inflamm
RCTs*	MeSH]; RCT [Keyword]; "randomized contro trial*" [Keyword]; randomized contro trial [MeSH]; randomized controlled as topic [MeSH]; "clinical trial*" [Key clinical trial [MeSH]; clinical trials as
Cohort/Observational Studies*	[MeSH] "observational study" [Keyword, Me "cohort study" [Keyword]; cohort study [MeSH]

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

Suggested Search Strings

Search Aspect #1: RCTs

(ERCP OR "endoscopic retrograde cholangiopancreatography") \rightarrow limit to RCTs

(ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" OR "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post-endoscopic retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OR haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystitis OR perforation OR cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation OR cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complication*" OR "treatment outcome*" OR inflammation OR rupture) \rightarrow limit to RCTs

Search Aspect #2: Cohort/Observational Studies

(ERCP OR "endoscopic retrograde cholangiopancreatography") \rightarrow limit to cohort/observational studies

(ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" OR "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post-endoscopic retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OR haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystitis OR perforation OR cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation OR cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complication*" OR "treatment outcome*" OR inflammation OR rupture)→limit to cohort/observational studies

MEDLINE (Ovid) Search Strategy

- ERCP.ab,ti.
 "endoscopic retrograde cholangiopancreatography".ab,ti.
 "improve tography".Endoscopic Retrograde/
- 4.1 or 2 or 3
- 5. "adverse event* ".ab.ti.
- 6. "adverse effect* ".ab,ti.
- 7. "adverse reaction* ".ab,ti.
 - 8. exp Long Term Adverse Effects/
 - 9. "post-ERCP pancreatitis".ab,ti.
 - 10. "post-endoscopic retrograde cholangiopancreatography pancreatitis".ab,ti.
 - 11. pancreatitis.ab,ti.
- 12. exp Pancreatitis/
- 13. exp Hemorrhage/
- 14. hemorrhage.ab,ti.
- 15. haemorrhage.ab,ti.
- 16. cholangitis.ab,ti.
- 59 60

2 3 17. exp Cholangitis/ 4 18. bleeding.ab,ti. 5 19. "infection*".ab,ti. 6 20. exp Infections/ 7 8 21. exp Cholecystitis/ 9 22. cholecystitis.ab,ti. 10 23. perforation.ab,ti. 11 24. cardiopulmonary.ab,ti. 12 25. sepis.ab,ti. 13 26. exp Sepsis/ 14 15 27. "complication*".ab,ti. 16 28. unplanned.ab,ti. 17 29. "event*".ab,ti. 18 30. sedation.ab,ti. 19 31. cholecystectomy.ab,ti. 20 32. exp Cholecystectomy/ 21 22 33. exp Choledocholithiasis/ 23 34. choledocholithiasis.ab,ti. 24 35. "risk factor* ".ab,ti. 25 36. exp Risk Factors/ 26 37. "postoperative complication* ".ab,ti. 27 38. exp Postoperative Complications/ 28 29 39. exp Treatment Outcome/ 30 40. "treatment outcome* ".ab,ti. 31 41. inflammation.ab,ti. 32 42. rupture.ab,ti. 33 43. exp Inflammation/ 34 35 44. exp Rupture/ 45. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 36 37 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 38 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 39 46. randomized controlled trial.pt. 40 47. clinical trial.pt. 41 42 48. randomi?ed.ti,ab. 43 49. placebo.ti,ab. 44 50. dt.fs. 45 51. randomly.ti,ab. 46 52. trial.ti,ab. 47 53. groups.ti,ab. 48 54. or/46-53 49 50 55. animals/ 51 56. humans/ 52 57.55 not (55 and 56) 53 58.54 not 57 54 59. RCT.ab,ti. 55 56 60. "randomized controlled trial* ".ab,ti. 57 58

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

	. "clinical trial* ".ab,ti.
	. exp Randomized Controlled Trial/
	. exp Randomized Controlled Trials as Topic/
	. exp Clinical Trial/
	. exp Clinical Trials as Topic/
	. 59 or 60 or 61 or 62 or 63 or 64 or 65
	. "observational study".ab,ti.
	. "cohort study".ab,ti.
	. exp Observational Study/
	. exp Cohort Studies/
71.	. 67 or 68 or 69 or 70
72.	. 4 and 45
	limit 72 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clin
tria	al, phase iii or clinical trial, phase iv or clinical trial protocol or clinical trial protoc
top	pic or clinical trial or controlled clinical trial or randomized controlled trial)
74.	. limit 72 to observational study
	limit 4 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clini
tria	al, phase iii or clinical trial, phase iv or clinical trial protocol or clinical trial protoc
top	pic or clinical trial or controlled clinical trial or randomized controlled trial)
76.	. limit 4 to observational study
77.	. 58 or 66
78.	. 4 and 77
	. 4 and 71
80.	. 75 or 78
81.	. 76 or 79
	. limit 80 to (english language and yr="2000 -Current")
	. limit 81 to (english language and yr="2000 -Current")
84.	. 72 and 77
85.	. 71 and 72
86.	. 73 or 84
	. 74 or 85
	. limit 86 to (english language and yr="2000 -Current")
89.	. limit 87 to (english language and yr="2000 -Current")
90.	. 82 or 83 or 88 or 89
91.	. remove duplicates from 90
Da	tabases

Medicine (EBM) Reviews

Limits

Language:EnglishPublication Date:2000 - present

Section and topic	Item No	Checklist item	Page
ADMINISTRATI	VE INI	FORMATION	
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as suchक्षे	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registragion number	2, 5
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	1
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	1
Sponsor	5b	Provide name for the review funder and/or sponsor	1
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol ද ද ද	N/A
INTRODUCTION	J		
Rationale	6	Describe the rationale for the review in the context of what is already known	4-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5

/bmjopen-2021-05

3 4

		BMJ Open	
		BMJ Open 	
METHODS		3302	
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5-6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage $\frac{8}{2}$	6-7
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, by cluding planned limits, such that it could be repeated	Tables 1,
Study records:		oade	
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7-8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, induding whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised 🛛 🖉	8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planed exploration of consistency (such as I ² , Kendall's τ)	8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta- regression)	8-9

Page	25	of	24
------	----	----	----

/bmjopen-2021

bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

1	
2	
3	
4	
5	
6	
/ 0	
0 9	
10	
11	
12	
13	
14	
15	
10	
18	
19	
20	
21	
22	
23	
$\begin{array}{c} 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 4\\ 35\\ 37\end{array}$	
26	
27	
28	
29	
30	
3 I 3 2	
33	
34	
35	
36	
37	
38 39	
40	
41	
42	
43	
44	
45	
46	

	15d	If quantitative synthesis is not appropriate, describe the type of summary planged	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias acrogs studies, selective reporting within studies)	8-9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) 토 문 장	9

* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Froup. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2915 Jan 2;349(jan02 1):g7647.

review on

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Adverse Events Associated with Endoscopic Retrograde Cholangiopancreatography: Protocol for a Systematic Review and Meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-053302.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Jul-2021
Complete List of Authors:	Forbes, Nauzer; University of Calgary, Medicine Leontiadis, GI ; McMaster University, Vaska, Marcus; Alberta Health Services, Knowledge Resource Service; Elmunzer, B.; Medical University of South Carolina Yuan, Yuhong ; McMaster University, Bishay, Kirles; University of Calgary, Medicine Meng, Zhao Wu; University of Calgary, Medicine Iannuzzi, Jordan; University of Calgary, Medicine O'Sullivan, Dylan; University of Calgary, Medicine Mah, Brittany; University of Calgary, Medicine Partridge, Arun; University of Calgary, Medicine Henderson, Amanda; University of Calgary, Medicine Qureshi, Aatif; University of Calgary, Medicine Keswani, Rajesh; Northwestern University Feinberg School of Medicine Wani, Sachin; University of Calgary, Medicine Heitman, Steven; University of Calgary, Medicine Hilsden, Robert; University of Calgary, Medicine Huisden, Robert; University of Calgary, Medicine Ruan, Yibing; Alberta Health Services, Cancer Epidemiology and Prevention Research Brenner, Darren; University of Calgary Cumming School of Medicine, Oncology
Primary Subject Heading :	Gastroenterology and hepatology
Secondary Subject Heading:	Evidence based practice
Keywords:	Endoscopy < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY, Pancreatic disease < GASTROENTEROLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

RELEX ONL

Adverse Events Associated with Endoscopic Retrograde Cholangiopancreatography: Protocol for a Systematic Review and **Meta-analysis**

Nauzer Forbes MD MSc^{1,2}, Grigorios I. Leontiadis MD PhD^{3,4}, Marcus Vaska MLIS⁵, B. Joseph Elmunzer MD MSc⁶, Yuhong Yuan PhD⁴, Kirles Bishay MD^{1,2}, Zhao Wu Meng MD^{1,2}, Jordan Iannuzzi MD¹, Dylan E. O'Sullivan PhD^{2,7}, Brittany Mah BSc¹, Arun C.R. Partridge MD¹, Amanda M. Henderson BSc¹, Aatif Qureshi MD¹, Rajesh N. Keswani MD MS⁸, Sachin Wani MD⁹, Ronald J. Bridges MD¹, Steven J. Heitman MD MSc^{1,2}, Robert J. Hilsden MD PhD^{1,2}, Yibing Ruan PhD MPH^{8,10}, Darren R. Brenner PhD^{2,8,10}

- Department of Medicine, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada
- Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada
- Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, ON, Canada
- Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada
- Knowledge Resource Service, Alberta Health Services, Calgary, AB, Canada
- Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC, USA
- Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
- Division of Gastroenterology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
- Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 10. Department of Cancer Epidemiology and Prevention Research, Cancer Control Alberta, Alberta Health Services, Calgary, AB, Canada

Corresponding Author:

Nauzer Forbes, MD, MSc

- Assistant Professor of Medicine
- Division of Gastroenterology
- University of Calgary
- TRW 6D19, 3280 Hospital Drive NW
- Tel: 403.592.5089 Fax: 403.592.5090 E-mail: nauzer.forbes@ucalgary.ca

AUTHOR CONTRIBUTIONS

- conception and design: NF, GIL
- analysis plan: NF, GIL, MV, YY, DEO, BJE, DRB
- drafting of the article: NF
- critical revision of the article for important intellectual content: NF, GIL, MV, BJE, YY, KB, ZWM, JI, DEO, BM, ACRP, AMH, AQ, RNK, SW, RJB, SJH, RJH, YR, DRB.
- final approval of the article: NF, GIL, MV, BJE, YY, KB, ZWM, JI, DEO, BM, ACRP, AMH, AQ, RNK, SW, RJB, SJH, RJH, YR, DRB.

DISCLOSURES/ CONFLICTS OF INTEREST

- None relevant.
 - The N.B. Hershfield Chair in Therapeutic Endoscopy (Grant number not applicable N/A).
- 236 (abstract); 2845 (main text).
- ERCP; endoscopic retrograde cholangiopancreatography; adverse event; pancreatitis;
- hemorrhage; cholangitis.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

ABSTRACT

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is performed to diagnose and manage conditions of the biliary and pancreatic ducts. Though effective, it is associated with common adverse events (AEs). The purpose of this study is to systematically review ERCP AE rates and report up-to-date pooled estimates.

Methods and Analysis

A comprehensive electronic search will be conducted of relevant medical databases through November 10, 2020. A study team of eight data abstracters will independently determine study eligibility, assess quality, and abstract data in parallel, with any two concordant entries constituting agreement and with discrepancies resolved by consensus. The primary outcome will be the pooled incidence of post-ERCP pancreatitis (PEP), with secondary outcomes including post-ERCP bleeding, cholangitis, perforation, cholecystitis, death, and unplanned healthcare encounters (UHE). Secondary outcomes will also include rates of specific and overall adverse events within clinically relevant subgroups determined a priori. DerSimonian and Laird random effects models will be used to perform meta-analyses of these outcomes. Sources of heterogeneity will be explored via meta-regression. Subgroup analyses based on median dates of data collection across studies will be performed to determine whether AE rates have changed over time.

23 Ethics and Dissemination

Our protocol was registered on PROSPERO (CRD42020220221). Ethics approval is not required for this study as it is a planned meta-analysis of previously published data. Participant consent is similarly not required. Dissemination is planned via presentation at relevant conferences in addition to publication in peer-reviewed journals.

1 2		
3 4	1	ARTICLE SUMMARY
4 5	2	
6 7	3	Strengths and Limitations of the Proposed Study
8	4	Our meta-analysis will provide to up-to-date estimates of procedural risks associated
9 10	5	with the performance of ERCP.
11	6	A comprehensive search strategy will be employed to capture all relevant studies and
12 13	7	answer our study question.
14 15	8	The strength of the body of evidence will be assessed using the Grading of
16	9	Recommendations, Assessment, Development and Evaluation (GRADE) framework.
17 18	10	A limitation of our approach is the likelihood of pooling outcome estimates using variable
19	11	definitions of outcomes across studies, which we will partially mitigate by performing
20 21	12	sensitivity analyses based on outcome definitions.
22 23	13	• Though the decision to exclude conference abstracts potentially disposes to publication
24	14	bias, we feel that the unclear or ambiguous methodology often available from
25 26	15	conference abstracts would add to potential study heterogeneity.
27	16	
28 29	17	
30 31	18	
32	19	
33 34	20	
35	21	
36 37	22	
38 39	23	
40	24	
41 42	25	
43	26	
44 45	27	
46 47	28	
48	29	
49 50	30	
51	31	
52 53	32	
54	33	
55 56	34	
57 58		
59		Ear peer review only - http://bmionon.hmi.com/site/about/auidalines.yhtml
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

1 INTRODUCTION

Endoscopic retrograde cholangiopancreatography (ERCP) is an essential and commonly performed advanced endoscopic procedure used in the diagnosis and treatment of several categories of biliary and pancreatic pathology.¹⁻⁴ Although the role of standard ERCP has transitioned to that of a primarily therapeutic procedure, ERCP volumes have nevertheless risen over the past 10-15 years in the United States (US).^{5, 6} ERCP is performed across high- and low-volume centers, and by endoscopists of variable experience and specialties.⁷ A steep learning curve during a specialized period of training results in an advanced skill set required to perform safe and effective ERCP.8,9

While very effective overall,¹⁰ ERCP is widely known to have the highest adverse event (AE) profile among all commonly performed endoscopic procedures, with a collective AE rate of >10%.¹¹ Common AEs include post-ERCP pancreatitis (PEP), bleeding, infection, cholecystitis, perforation, and cardiopulmonary events.^{11, 12} PEP is the most common, with estimated rates of 5-10% in all-comers, approaching or exceeding 20% in higher-risk cases.¹¹⁻¹³ Despite an emphasis on training and quality, both the incidence of PEP and its associated mortality are rising in the US.¹⁴ Rates of post-ERCP bleeding range between 0.3% and 2%.¹⁵⁻¹⁷ Symptomatic post-ERCP infection (cholangitis with or without sepsis) is also a common AE following ERCP, with a reported range between 0.5% and 3%,¹¹ and is of particular interest in recent years given the rise of duodenoscope-related infections.18-21

ERCP AEs are commonly reported in studies of varying designs; however, few systematic reviews have synthesized available incidence rates of specific or overall AEs following ERCPs. A 2015 study synthesized the rates of PEP from randomized trials,¹³ but their search is now nearly 8 years out of date. Furthermore, other adverse event rates were not considered, and observational studies were not included. Observational studies are a required element of understanding true population rates of AEs,^{22, 23} given that the patient mixes therein are more representative of the actual patient population in clinical practice compared to the highly selected

BMJ Open

participants in randomized trials. Given the frequency with which these events occur and their significant burden on the healthcare system,^{24, 25} it is crucial to obtain accurate, up-to-date data on which to base estimates of incidence. Furthermore, AE rates differ depending on clinically relevant patient- and procedure-related parameters, but pooled estimates of incidences within these subgroups are largely unavailable. These estimates could be important so that patients and endoscopists are aware of specific risks associated with each procedure.

Prior meta-analyses on this topic have focused only on pediatric patients²⁶ or instead on specific AEs or specific patient subgroups.^{13, 27, 28} Therefore, we propose an up-to-date, comprehensive, and methodologically rigorous systematic review and meta-analysis to determine the incidence of adverse events following ERCP in adult patients, both overall and within clinically relevant patient- and procedure-related subgroups.

- **METHODS**

Overview and Objectives

Our meta-analysis will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) recommendations.^{29, 30}

The primary objective will be to determine the pooled overall incidence of PEP (the primary outcome) in adult patients undergoing ERCP. The secondary objectives will be to determine the pooled incidences of post-ERCP bleeding, cholangitis, perforation, cholecystitis, death, and unplanned healthcare encounters, in addition to determining the rates of specific and overall adverse events within clinically relevant subgroups determined a priori and described below.

Eligibility Criteria

Given the comprehensive nature of the study question and outcomes of interest, two separate electronic searches will be conducted, with studies captured within either search being

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

eligible for inclusion in the overall systematic review. The first search will focus on randomized trials only, while the second search will also include observational studies. For the first search, a study will be included in the final review if it meets all of the following criteria: (1) it presents original data in the form of a randomized clinical trial (with any primary research question), (2) the interventional arm or control arm represents adult patients receiving ERCP, (3) it makes reference to the determination of overall or specific ERCP-related adverse event(s) as a primary or secondary outcome; (4) it reports the incidence of at least one post-ERCP adverse event (including any of PEP, bleeding, symptomatic infection or cholangitis, perforation, cholecystitis, death, or unplanned presentation to a healthcare facility within any follow-up period up to 30 days after the index procedure); (5) it is published in English; and (6) at least 75% of study patients received their ERCP in the year 2000 or later. The year 2000 was chosen as a cut-off so that only studies representative of the current 'era' of ERCP are included. For the first search, a study will be excluded from the review if (1) it is a conference abstract; or (2) if it reports data that overlaps with another study's patient population in part or in whole for the same outcome of interest. In the latter case, the study that includes the largest number of patients that had their ERCP conducted in the year 2000 or later will be included while any others are excluded.

For the second search, a study will be included in the final review if it meets all of the following criteria: (1) it is an observational study of any design; (2) its primary or secondary objective is to assess post-ERCP adverse event rates or outcomes in adults; (3) it reports the incidence of a specific post-ERCP adverse event, including any of the following: PEP, bleeding, symptomatic infection or cholangitis, perforation, cholecystitis, death, or unplanned presentation to a healthcare facility within 30 days of the index procedure; (4) it is published in English; and (5) at least 75% of study patients received their ERCP in the year 2000 or later. For the second search, a study will be excluded from the review if it meets any of the following criteria: (1) it is a case report; (2) it is a smaller study (fewer than 500 total study patients, with this threshold set to mitigate small study effects due to random error and to reduce the likelihood of including zero-

BMJ Open

event studies, which are problematic to meta-analyze); (3) it represents the experience of a single endoscopist; (4) it is a conference abstract; or (5) it reports data that overlaps with another study's patient population in part or in whole for the same outcome. In the latter case, the study that includes the largest number of patients that had their ERCP conducted in the year 2000 or later will be included while any others are excluded. Eligibility criteria for both aspects of the overall search strategy are summarized in **Table 1**.

8 Search Strategy and Terms

A comprehensive electronic search will be designed by a health research librarian and carried out in the electronic databases MEDLINE (Ovid), PubMed, CINAHL, EMBASE, Scopus, Web of Science, and Evidence Based Medicine (EBM) Reviews based on the eligibility criteria detailed above, from inception of each data source to the search date of November 10, 2020. English language citations from 2000 or later will be included. A combination of Medical Subject Heading (MeSH) and free-text terms will be used along with spelling variations and synonyms to create the two search strategies outlined above. A detailed list of search terms is provided in Table 2, with a full search planning document provided in the Supplementary Materials.

18 Study Selection and Data Abstraction

All citations will be imported into DistillerSR (Evidence Partners, Ottawa, Canada) and any duplicate entries will be removed. Given the large volume of anticipated citations identified in the initial searches, 8 reviewers (KB, ZWM, JI, DEO, BM, ACRP, AMH, AQ) will be randomly assigned roughly equal numbers of citations. Assessments by the first 2 reviewers will be used for titles and abstracts to identify citations for potential full-text review. A vote of 'both include' or 'both exclude' by any 2 of the 8 reviewers will be considered definitive. Discrepancies will be resolved by consensus of an *a priori* committee of study investigators (NF, YR, DRB). All included citations will then undergo independent duplicate full-text abstraction by 2 reviewers (of the same pool of

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

8), with discrepancies again being resolved by consensus. Data will then be extracted into standardized abstraction forms in duplicate, with separate forms for each aspect of the search strategy. Forms will include authors, year of publication, study design, country(ies) in which the research was carried out, study setting, recruitment period, sample sizes, patient sex, age, and comorbidity, procedural indication(s), relevant pre-procedural parameters (including imaging studies and bilirubin levels) description of intervention(s), rates of adverse events (in absolute numbers and proportions), outcome definitions and follow-up periods. Where possible, the severity of AEs will also be captured, including as an example mild, moderate, and severe pancreatitis according to the Atlanta classification,³¹ so that pooled data can also be reported according to severity. Data will be abstracted both on the patient level as well as the procedure level, as available. Relevant subgroups (Table 3) will also be abstracted.

Outcome Definitions

A challenge with pooling rates of ERCP AEs is that non-universal definitions of outcomes are employed across studies. Detailed study-specific outcome definitions will be abstracted to help address this issue. Outcome definitions will be compared against those described in the American Society for Gastrointestinal Endoscopy (ASGE) Lexicon³² and the European Society for Gastrointestinal Endoscopy (ESGE) Guideline.³³ Studies not reporting clear outcomes definitions or those employing non-guideline/lexicon definitions will be flagged for sensitivity analyses. Study-specific mechanisms of outcome capture will also be abstracted so that these can be considered separately.³⁴ For the primary outcome (PEP), the ASGE Lexicon definition requires typical pain with amylase or lipase greater than 3 times the upper limit of normal.³²

Risk of Bias

Two authors will independently conduct risk of bias assessments for all included studies. Assessment of included randomized studies will be performed using the Cochrane Risk of Bias

tool, version 2 (RoB 2),³⁴ while the quality of observational studies will be assessed using the
 ROBINS-I tool.³⁵ Discrepancies will be resolved by consensus.

4 Statistical Analysis, Subgroup and Sensitivity Analyses

We will perform DerSimonian and Laird random effects meta-analyses to report the pooled incidence rates of individual post-ERCP AEs along with 95% confidence intervals (CIs). Study weights will be measured using the inverse variance method. Incidence rates from observational studies and randomized trials will be pooled separately (at no point being combined). Heterogeneity between studies will be assessed with the I² and χ^2 statistics. We will consider p values of <0.10 for the χ^2 statistic or an I² value >50% to indicate substantial heterogeneity, which will be further investigated with subgroup analyses. Subgroup analyses will be performed using relevant study-, procedure- and patient-related characteristics selected a priori. These are summarized in **Table 3**. In addition, sources of heterogeneity will also be tested by performing meta-regression on these a priori selected characteristics. We will examine the I² and adjusted R^2 statistics to estimate the fraction of heterogeneity accounted for by these characteristics.

To determine whether adverse event rates have changed over time, we will perform subgroup analyses based on the median dates of data collection in individual studies for each type of adverse event. Median data collection will be assigned a single value per study and studies will be separated into three periods: a) 2000-2009, b) 2010-2014, and c) 2015-present. Meta-regression will be performed to determine whether there are any significant differences in specific or overall AE rates between periods. Periods were chosen based on the 2012 publication of the seminal manuscript on rectal non-steroidal anti-inflammatory agents to prevent PEP³⁶ and a 3-year lag period between study dissemination and clinical practice adoption.

We will also conduct a series of sensitivity analyses whereby studies of varying quality as
 per ROBINS-I and RoB 2 are considered separately and whereby studies employing non-ASGE lexicon AE definitions will be considered separately. Inter-study heterogeneity will be assessed

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

using the Cochrane *l*² statistic. Publication bias will be assessed by visual inspection of funnel plots in addition to performing Egger's and Begg's tests.^{37, 38} The statistical packages Revman 5.1 (Cochrane Collaboration) and Stata 14.0 (StataCorp) will be used for all analyses. The strength of the body of evidence will then be assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework.³⁹

Patient and Public Involvement

No patients or public were involved in study design.

10 ETHICS AND DISSEMINATION

11 Our protocol was registered on PROSPERO (CRD42020220221). Ethics approval is not 12 required for this study as it is a planned meta-analysis of previously published data. Participant 13 consent is similarly not required. Dissemination is planned via presentation at relevant 14 conferences in addition to publication in peer-reviewed journals.

16 DISCUSSION

This systematic review and meta-analysis will provide up-to-date estimates of incidences of the most common adverse events associated with the performance of ERCP. Though ERCP in 2020 is primarily a therapeutic procedure, with minimal diagnostic indications, it remains one of the most commonly performed endoscopic procedures in the US and world-wide, with volumes having increased over time.^{5, 6} Even though ERCP is a relatively safe procedure overall, AEs are more prevalent with its performance than any other endoscopic procedure. Thus, it behooves endoscopists performing ERCP to be acutely aware of the most precise and up-to-date estimates of risk possible. If possible, patient- and procedure-specific estimates of risk should also be ascertained, which is also a goal of the proposed study. Obtaining these estimates could help set

BMJ Open

up appropriate patient expectations of risk and could also serve to optimize the peri-procedural management of ERCP patients.

Specific knowledge gaps are particularly important to bridge regarding ERCP AEs. In particular, accurate estimates of the rate of post-ERCP symptomatic infections (cholangitis or sepsis) are particularly important given the growing concerns around duodenoscope-related infections.¹⁸⁻²¹ Obtaining accurate estimates of the overall burden of post-ERCP infection is the first step toward describing the relatively smaller infection risk attributable directly to duodenoscope contamination and transmission. Similarly, estimates of post-sphincterotomy and/or post-sphincteroplasty bleeding are variable,¹⁵⁻¹⁷ and no pooled estimates to date are available. With regards to rarer AEs such as cholecystitis and perforation, evidence is even more scarce. Thus, an urgent but unmet need is present to accurately define the overall and specific AE profile associated with ERCP.

Though this protocol was designed to limit sources of bias through rigorous methodology, there are nevertheless potential limitations that require acknowledgment. As with any meta-analysis, the certainty of pooled estimates is limited by the quality of input studies. With this topic in particular, it is anticipated that study cohorts will be described using variable levels of detail regarding demographics, comorbidities, procedural indications, and procedural interventions. To mitigate this, we divided our study into two main analyses; the first, inclusive of randomized controlled trials, is expected to be more granular in terms of these details and is thus expected to yield more robust patient- and procedure-specific estimates of risk. The second, inclusive of only large observational studies, is expected to yield more pragmatic 'real-world' estimates of risk. For this analysis, a pre-set cutoff point of 500 patients was chosen to mitigate small study effects. The 'delta', or gap between these two types of estimates, will also be a crucial aspect of our findings that we plan on discussing as it relates to implications on evidence interpretation and on clinical practice.

BMJ Open: first published as 10.1136/bmjopen-2021-053302 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

Another limitation of our approach is the possibility of pooling outcome estimates using variable definitions of outcomes across studies. To mitigate this, we will abstract study-specific outcome definitions and perform sensitivity analyses whereby studies with unclear or absent definitions are separately analyzed. Even with this approach, we expect there to be some degree of (acceptable) variability between study definitions, but we will compare study-specific definitions against the ASGE Lexicon's AE definitions³² to ensure that we only pool studies adhering to minimal thresholds for attribution of AEs. For instance, for post-ERCP bleeding, we will ensure that at minimum, studies require a hemoglobin drop of > 2 g as part of their definition, in order to prevent inclusion of patients with intraprocedural or non-clinically-significant post-procedural bleeding, which has been demonstrated to be of limited consequence.¹² Another limitation includes missing studies due to our decision to restrict our inclusions to English studies with the majority of data collected after the year 2000. While this is a valid concern, we felt it was more important to capture evidence most representative of current practices, techniques and technologies. Therefore, studies with a significant volume of study procedures performed prior to the year 2000 were deemed to be at risk of not representing current ERCP practice. Finally, we have made the decision to exclude conference abstracts from our study. Though this potentially disposes to publication bias, we feel that the unclear or ambiguous methodology often available from conference abstracts would add to potential study heterogeneity.

Overall, despite these limitations, we anticipate that our study will bridge important knowledge gaps pertaining to ERCP-associated adverse events. Our results could potentially improve patient care and satisfaction by providing more detailed and up-to-date estimates of ERCP-related risk. Accurate AE estimates will also facilitate the design of future prospective ERCP studies including randomized trials and could potentially have meaningful implications on training and practice standards.

2	Inclusion criteria	Exclusion criteria
Search Aspect 1	 original data randomized controlled trial (with any research question) interventional OR control arm of RCT represents adult patients receiving ERCP an adverse event is a primary and/or secondary outcome 	 non-English publication data overlaps with data from another study (in part or in whother study (in part or in whother study procedures performed prior to 2000 conference abstract
Search Aspect 2	 original data observational study (prospective or retrospective) reports on adult patients receiving ERCP primary or secondary objective of study is determination of ERCP adverse event(s) 	 small cohort of patients (fewer than 500) represents the experience of a single endoscopist non-English publication data overlaps with data from another study (in part or in who over 25% of study procedures performed prior to 2000 conference abstract
3 RCT, randomiz	ed controlled trial; ERCP, endoscopic retr	
4		
5 6		
7		
8		
9		
0		
1		
2		
3		
4		
5		
6		
7		
8		
9		
0		
1		

	Search Aspect 1: Randomized Controlled Trials
	(ERCP OR "endoscopic retrograde cholangiopancreatography")→limit to RCTs
	(ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post-endosc retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OF haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystitis OR perforatio cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation O cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complicatio OR "treatment outcome*" OR inflammation OR rupture)→limit to RCTs
	Search Aspect 2: Observational Studies
	(ERCP OR "endoscopic retrograde cholangiopancreatography")→limit to cohort/observa studies (ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post-endosc retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OF haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystitis OR perforation cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation O cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complication OR "treatment outcome*" OR inflammation OR rupture)→limit to cohort/observational st
*F	Full electronic search strategy provided in Supplementary Materials .

2 3 4	1 <u>Ta</u>	ble 3. Planned subgroup analyses.
5 6 7	Category	Subgroups
8 9 10 11 12 13 14 15 16 17	Patient demographics and characteristics	 Female versus male sex Age < 50 versus ≥ 50 Inpatient versus outpatient status Degree of comorbidity (Charlson Comorbidity Index or other, TBD) Underlying primary sclerosing cholangitis Liver transplant status Presence of antiplatelet or anticoagulant medications Presence versus absence of PEP prophylaxis
18 19 20	Practice settings	 Academic institutions versus community practices Low-volume versus high-volume centers and/or endoscopists (cutoff points TBD)
21 22 23 24 25	Procedural indications	 Pancreatic versus biliary indications Choledocholithiasis (suspected or confirmed) Malignant obstruction Benign obstruction
26 27 28 29 30 31 32 33	Intra-procedural techniques	 Sphincterotomy Sphincteroplasty Pre-cut sphincterotomy Needle knife papillotomy Biliary stent placement Mechanical lithotripsy Cholangioscopy and/or pancreatoscopy Pancreatic versus common bile duct cannulation
34 35 36 37 38 39 40 41 42	Study methodology	 North American versus European versus Asian-Pacific Study publication date Median data collection date (2000-2009, 2010-2014, 2015-present) Study design (retrospective versus prospective observational versus randomized controlled trial) ASGE Lexicon versus non-lexicon definition(s) of
54 1	 3 PEP, post-ERCP pancreatitis; 4 Gastrointestinal Endoscopy. 5 6 7 8 9 10 11 12 	DBD, to be determined; ASGE, American Society for
59 60	For peer review or	1: hly - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ	Open
-----	------

REFERENCES

4	2		
5			
6	3	1.	Maple JT, Ikenberry SO, Anderson MA, et al. The role of endoscopy in the management
7	4		of choledocholithiasis. Gastrointest Endosc 2011;74:731-44.
8	5	2.	Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of
9	6		the biliary tract and the pancreas. Gastrointest Endosc 2005;62:1-8.
10	7	3.	Anderson MA, Appalaneni V, Ben-Menachem T, et al. The role of endoscopy in the
11	8	5.	evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc
12			
13	9		2013;77:167-74.
14	10	4.	Chandrasekhara V, Chathadi KV, Acosta RD, et al. The role of endoscopy in benign
15	11	_	pancreatic disease. Gastrointest Endosc 2015;82:203-14.
16	12	5.	Kroner PT, Bilal M, Samuel R, et al. Use of ERCP in the United States over the past
17	13		decade. Endoscopy International Open 2020;8:E761.
18	14	6.	Ahmed M, Kanotra R, Savani GT, et al. Utilization trends in inpatient endoscopic
19	15		retrograde cholangiopancreatography (ERCP): A cross-sectional US experience.
20	16		Endosc Int Open 2017;5:E261-e271.
21	17	7.	Testoni PA, Mariani A, Giussani A, et al. Risk factors for post-ERCP pancreatitis in high-
22	18		and low-volume centers and among expert and non-expert operators: a prospective
23	19		multicenter study. Am J Gastroenterol 2010;105:1753-61.
24	20	8.	Wani S, Keswani RN, Han S, et al. Competence in Endoscopic Ultrasound and
25	21	0.	Endoscopic Retrograde Cholangiopancreatography, From Training
26	22		Through Independent Practice. Gastroenterology 2018;155:1483-1494.e7.
27	23	9.	Wani S, Han S, Simon V, et al. Setting minimum standards for training in EUS and
28		9.	
29	24		ERCP: results from a prospective multicenter study evaluating learning curves and
30	25		competence among advanced endoscopy trainees. Gastrointest Endosc 2019;89:1160-
31	26		1168.e9.
32	27	10.	Mariani A, Segato S, Anderloni A, et al. Prospective evaluation of ERCP performance in
33	28		an Italian regional database study. Dig Liver Dis 2019;51:978-984.
34	29	11.	Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Adverse events associated with
35	30		ERCP. Gastrointest Endosc 2017;85:32-47.
36	31	12.	Rustagi T, Jamidar PA. Endoscopic retrograde cholangiopancreatography-related
37	32		adverse events: general overview. Gastrointest Endosc Clin N Am 2015;25:97-106.
38	33	13.	Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, and mortality of post-
39	34		ERCP pancreatitis: a systematic review by using randomized, controlled trials.
40	35		Gastrointest Endosc 2015;81:143-149.e9.
41	36	14.	Mutneja H, Vohra I, Go A, et al. Temporal Trends and Mortality of Post-Endoscopic
42	37		Retrograde Cholangiopancreatography Pancreatitis in the United States: A Nationwide
43	38		Analysis. Endoscopy 2020.
44	39	15.	Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a
45	40	15.	•
46			multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc
47	41	40	2009;70:80-8.
48	42	16.	Christensen M, Matzen P, Schulze S, et al. Complications of ERCP: a prospective study.
49	43		Gastrointest Endosc 2004;60:721-31.
50	44	17.	Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary
51	45		sphincterotomy. N Engl J Med 1996;335:909-18.
52	46	18.	Preventable tragedies: Superbugs and How Ineffective Monitoring of Medical Device
53	47		Safety Fails Patients In: U.S. Senate Health E, Labor, and Pensions Committee, ed,
54	48		2016.
55			
56			
57			
58			
50			

BMJ Open

2			
3	1	19.	Muscarella LF. Risk of transmission of carbapenem-resistant Enterobacteriaceae and
4	2		related "superbugs" during gastrointestinal endoscopy. World J Gastrointest Endosc
5	3		2014;6:457-74.
6	4	20.	Forbes N, Heitman S, McCulloch P. Infection Control in ERCP: a Human Factors
7		20.	
8	5	04	Perspective. Clin Transl Gastroenterol 2020;11:e00214.
9	6	21.	Humphries RM, McDonnell G. Superbugs on Duodenoscopes: the Challenge of
10	7		Cleaning and Disinfection of Reusable Devices. J Clin Microbiol 2015;53:3118-25.
11	8	22.	Page MJ, McKenzie JE, Kirkham J, et al. Bias due to selective inclusion and reporting of
12	9		outcomes and analyses in systematic reviews of randomised trials of healthcare
13	10		interventions. Cochrane Database Syst Rev 2014:Mr000035.
14	11	23.	Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from
15	12		randomised controlled trials as compared to observational studies: methodological
16	13		overview. PLoS Med 2011;8:e1001026.
17	14	24.	Fagenholz PJ, Fernández-del Castillo C, Harris NS, et al. Direct medical costs of acute
18	15		pancreatitis hospitalizations in the United States. Pancreas 2007;35:302-7.
19	16	25.	Inamdar S, Sejpal DV, Ullah M, et al. Weekend vs. Weekday Admissions for Cholangitis
20	10	20.	
20			Requiring an ERCP: Comparison of Outcomes in a National Cohort. Am J Gastroenterol
22	18	00	2016;111:405-10.
23	19	26.	Usatin D, Fernandes M, Allen IE, et al. Complications of Endoscopic Retrograde
24	20		Cholangiopancreatography in Pediatric Patients; A Systematic Literature Review and
25	21		Meta-Analysis. J Pediatr 2016;179:160-165.e3.
26	22	27.	Mashiana HS, Dhaliwal AS, Sayles H, et al. Endoscopic retrograde
20	23		cholangiopancreatography in cirrhosis - a systematic review and meta-analysis focused
27	24		on adverse events. World J Gastrointest Endosc 2018;10:354-366.
20 29	25	28.	Iqbal U, Anwar H, Khan MA, et al. Safety and Efficacy of Endoscopic Retrograde
30	26		Cholangiopancreatography in Nonagenarians: A Systematic Review and Meta-Analysis.
30 31	27		Dig Dis Sci 2021.
32	28	29.	Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review
32 33	29		and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
	30	30.	Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in
34 25	31	50.	epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in
35	32		Epidemiology (MOOSE) group. Jama 2000;283:2008-12.
36		24	
37	33	31.	Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis2012:
38	34		revision of the Atlanta classification and definitions by international consensus. Gut
39	35	~~	2013;62:102-11.
40	36	32.	Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events:
41	37		report of an ASGE workshop. Gastrointest Endosc 2010;71:446-54.
42	38	33.	Dumonceau JM, Kapral C, Aabakken L, et al. ERCP-related adverse events: European
43	39		Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2020;52:127-149.
44	40	34.	Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, 2011.
45	41	35.	Sterne J, Hernan M, Reeves B, et al. ROBINS-I: a tool for assessing risk of bias in non-
46	42		randomised studies of interventions. BMJ 2016;355:i4919.
47	43	36.	Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal
48	44		indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-22.
49	45	37.	Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a
50	46	07.	simple, graphical test. Bmj 1997;315:629-34.
51	47	38.	Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for
52		50.	••
53	48	20	publication bias. Biometrics 1994;50:1088-101.
54	49	39.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality
55	50		of evidence and strength of recommendations. Bmj 2008;336:924-6.
56	51		
57			
58			
59			For peer review only http://hmienen.hmi.com/cite/about/cuidelines.yhtml
60			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 2	
3 4	
5 6	
7 8	
9 10	
11	
12 13	
14 15	
16 17	
18	
19 20	
21 22	
23 24	
25 26	
27	
28 29	
30 31	
32 33	
34 35	
36 37	
38	
39 40	
41 42	
43 44	
45 46	
47	
48 49	
50 51	
52 53	
54	
55 56	
57 58	
59 60	

Supplementary Materials -	Search Planning Document
11 5	8

Concept	Synonym
ERCP	ERCP [Keyword]; "endoscopic retrograde
	cholangiopancreatography" [Keyword];
	cholangiopancreatography, endoscopic
	retrograde [MeSH]
Adverse Events	"adverse event*" [Keyword]; "adverse
	effect*" [Keyword]; "adverse reaction*"
	[Keyword]; long term adverse effects
	[MeSH]; "post-ERCP pancreatitis"
	[Keyword]; "post-endoscopic retrograde
	cholangiopancreatography pancreatitis"
	[Keyword]; pancreatitis [Keyword, MeSH
	hemorrhage [Keyword, MeSH];
	haemorrhage [Keyword]; cholangitis
	[Keyword, MeSH]; bleeding [Keyword];
	infection* [Keyword]; infections [MeSH];
	cholecystitis [Keyword, MeSH]; perforation
	[Keyword]; cardiopulmonary [Keyword];
	sepsis [Keyword, MeSH]; complication*
	[Keyword]; unplanned [Keyword]; event
	[Keyword]; sedation [Keyword];
	cholecystectomy [Keyword, MeSH];
	choledocholithiasis [Keyword, MeSH]; "ri
	factor*" [Keyword]; risk factors [MeSH];
	"postoperative complication*" [Keyword]
	postoperative complications [MeSH];
	"treatment outcome*" [Keyword];
	treatment outcome [MeSH]; inflammation
	[Keyword, MeSH]; rupture [Keyword,
	MeSH];
RCTs*	RCT [Keyword]; "randomized controlled
	trial*" [Keyword]; randomized controlled
	trial [MeSH]; randomized controlled trial
	as topic [MeSH]; "clinical trial*" [Keyword
	clinical trial [MeSH]; clinical trials as topic
	[MeSH]
Cohort/Observational Studies*	"observational study" [Keyword, MeSH];
	"cohort study" [Keyword]; cohort studies
	[MeSH]

*a combination of MeSH headings, publication types, and methodological search filters, https://guides.library.ualberta.ca/health-sciences-search-filters/study-type-filters will be used

4 5

6 7

8 9 10

11

12

13

14

15 16

17

18 19

20 21 22

23

24 25

26

27

28 29

30

31

32

33

34 35 36

43

44

45

46

47

48

49 50

51

52

53

55 56

Suggested Search Strings

Search Aspect #1: RCTs

(ERCP OR "endoscopic retrograde cholangiopancreatography") \rightarrow limit to RCTs

(ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" OR "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post-endoscopic retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OR haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystitis OR perforation OR cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation OR cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complication*" OR "treatment outcome*" OR inflammation OR rupture) \rightarrow limit to RCTs

Search Aspect #2: Cohort/Observational Studies

(ERCP OR "endoscopic retrograde cholangiopancreatography") \rightarrow limit to cohort/observational studies

(ERCP OR "endoscopic retrograde cholangiopancreatography") AND ("adverse event*" OR "adverse effect*" OR "adverse reaction*" OR "post-ERCP pancreatitis" OR "post-endoscopic retrograde cholangiopancreatography pancreatitis" OR pancreatitis OR hemorrhage OR haemorrhage OR cholangitis OR bleeding OR infection* OR cholecystitis OR perforation OR cardiopulmonary OR sepsis OR complication* OR unplanned OR event* OR sedation OR cholecystectomy OR choledocholithiasis OR "risk factor*" OR "postoperative complication*" OR "treatment outcome*" OR inflammation OR rupture)→limit to cohort/observational studies

MEDLINE (Ovid) Search Strategy

- ERCP.ab,ti.
 "endoscopic retrograde cholangiopancreatography".ab,ti.
 "improve tography".Endoscopic Retrograde/
- 4.1 or 2 or 3
- 5. "adverse event* ".ab.ti.
- 6. "adverse effect* ".ab,ti.
- 7. "adverse reaction* ".ab,ti.
 - 8. exp Long Term Adverse Effects/
 - 9. "post-ERCP pancreatitis".ab,ti.
 - 10. "post-endoscopic retrograde cholangiopancreatography pancreatitis".ab,ti.
 - 11. pancreatitis.ab,ti.
- 12. exp Pancreatitis/
- 13. exp Hemorrhage/
- 14. hemorrhage.ab,ti.
- 54 15. haemorrhage.ab,ti.
 - 16. cholangitis.ab,ti.
- 57 58

2 3 17. exp Cholangitis/ 4 18. bleeding.ab,ti. 5 19. "infection*".ab,ti. 6 20. exp Infections/ 7 8 21. exp Cholecystitis/ 9 22. cholecystitis.ab,ti. 10 23. perforation.ab,ti. 11 24. cardiopulmonary.ab,ti. 12 25. sepis.ab,ti. 13 26. exp Sepsis/ 14 15 27. "complication*".ab,ti. 16 28. unplanned.ab,ti. 17 29. "event*".ab,ti. 18 30. sedation.ab,ti. 19 31. cholecystectomy.ab,ti. 20 32. exp Cholecystectomy/ 21 22 33. exp Choledocholithiasis/ 23 34. choledocholithiasis.ab,ti. 24 35. "risk factor* ".ab,ti. 25 36. exp Risk Factors/ 26 37. "postoperative complication* ".ab,ti. 27 38. exp Postoperative Complications/ 28 29 39. exp Treatment Outcome/ 30 40. "treatment outcome* ".ab,ti. 31 41. inflammation.ab,ti. 32 42. rupture.ab,ti. 33 43. exp Inflammation/ 34 35 44. exp Rupture/ 36 45. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 37 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 38 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 39 46. randomized controlled trial.pt. 40 47. clinical trial.pt. 41 42 48. randomi?ed.ti,ab. 43 49. placebo.ti,ab. 44 50. dt.fs. 45 51. randomly.ti,ab. 46 52. trial.ti,ab. 47 53. groups.ti,ab. 48 54. or/46-53 49 50 55. animals/ 51 56. humans/ 52 57.55 not (55 and 56) 53 58.54 not 57 54 59. RCT.ab,ti. 55 56 60. "randomized controlled trial* ".ab,ti. 57 58

59 60

1	
2	
3	74 -] - -
4	61. "clinical trial* ".ab,ti.
5	62. exp Randomized Controlled Trial/
6	63. exp Randomized Controlled Trials as Topic/
7	64. exp Clinical Trial/
8	65. exp Clinical Trials as Topic/
9	66. 59 or 60 or 61 or 62 or 63 or 64 or 65
10	67. "observational study".ab,ti.
11	
12	68. "cohort study".ab,ti.
13	69. exp Observational Study/
14	70. exp Cohort Studies/
15	71. 67 or 68 or 69 or 70
16	72. 4 and 45
17	73. limit 72 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical
18	trial, phase iii or clinical trial, phase iv or clinical trial protocol or clinical trial protocols as
19	
20	topic or clinical trial or controlled clinical trial or randomized controlled trial)
21	74. limit 72 to observational study
22	75. limit 4 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical
23	trial, phase iii or clinical trial, phase iv or clinical trial protocol or clinical trial protocols as
24	topic or clinical trial or controlled clinical trial or randomized controlled trial)
25	76. limit 4 to observational study
26	77. 58 or 66
27 28	78. 4 and 77
28 29	
30	79. 4 and 71
31	80. 75 or 78
32	81. 76 or 79
33	82. limit 80 to (english language and yr="2000 -Current")
34	83. limit 81 to (english language and yr="2000 -Current")
35	84. 72 and 77
36	85. 71 and 72
37	86. 73 or 84
38	
39	87. 74 or 85
40	88. limit 86 to (english language and yr="2000 -Current")
41	89. limit 87 to (english language and yr="2000 -Current")
42	90. 82 or 83 or 88 or 89
43	91. remove duplicates from 90
44	
45	Databases
46	
47	MEDI INE (Arid), Dubmod. CINALIL, EMDACE Commentation of Comments
48	MEDLINE (Ovid); PubMed; CINAHL; EMBASE; Scopus; Web of Science; Evidence-Based

MEDLINE (Ovid); PubMed; CINAHL; EMBASE; Scopus; Web of Science; Evidence-Based Medicine (EBM) Reviews

Limits

49 50 51

52 53

54

60

Language:EnglishPublication Date:2000 - present

Section and topic	Item No	Aug	Page
ADMINISTRATI	VE IN	FORMATION	
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2, 5
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	1
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	1
Sponsor	5b	Provide name for the review funder and/or sponsor	1
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	N/A
INTRODUCTION	J	st. P	
Rationale	6	Describe the rationale for the review in the context of what is already known ${egin{array}{c}{3}}$	4-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5

BMJ Open PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 25 of 24

		BMJ Open	
		BMJ Open 	
METHODS		30 20 2	
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5-6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage $\frac{8}{2}$	6-7
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, $\frac{1}{5}$	Tables 1,
Study records:		oade	
Data management		Describe the mechanism(s) that will be used to manage records and data throughout the review	7
Selection process	11b	State the process that will be used for selecting studies (such as two independes t reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7-8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, induding whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I², Kendall's τ)	8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta- regression)	8-9

 /bmjopen-2021

/bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

		0 5	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planr $\overset{ar{w}}{\mathrm{g}}$ d	N/A
Meta-bias(es)		Specify any planned assessment of meta-bias(es) (such as publication bias acrogs studies, selective reporting within studies)	8-9
Confidence in	17	Describe how the strength of the body of evidence will be assessed (such as GR DE)	9
cumulative		, st	
evidence			
* It is strongly i	recom	mended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaborat	ion (cite

It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons **Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Broup. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2215 Jan 2;349(jan02 1):g7647. njopen....

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml